Shandong Realcan Pharmaceutical Co Ltd (002589) — Strategic Asset Allocation Index
Shandong Realcan Pharmaceutical Co Ltd (002589) has a Strategic Asset Allocation Index of 40.0% as of September 2023. Strategic assets (PP&E of CN¥2.28 Billion plus long-term investments of CN¥-) total CN¥2.28 Billion, measured against net assets of CN¥5.70 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Shandong Realcan Pharmaceutical Co Ltd Strategic Asset Allocation Index (2008–2022)
This chart shows how Shandong Realcan Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of September 2023, the index stands at 40.0%, representing strategic assets of CN¥2.28 Billion against net assets of CN¥5.70 Billion CNY. Explore cash flow conversion of Shandong Realcan Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Shandong Realcan Pharmaceutical Co Ltd (2008–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 002589 market cap.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 39.9% | CN¥2.30 Billion | CN¥2.30 Billion | CN¥- | CN¥5.75 Billion | ▲ +13.9 pp |
| 2021 | 26.1% | CN¥2.53 Billion | CN¥2.53 Billion | CN¥- | CN¥9.69 Billion | ▼ -7.0 pp |
| 2020 | 33.1% | CN¥3.19 Billion | CN¥3.19 Billion | CN¥- | CN¥9.64 Billion | ▲ +7.2 pp |
| 2019 | 25.9% | CN¥2.65 Billion | CN¥2.65 Billion | CN¥- | CN¥10.25 Billion | ▲ +5.2 pp |
| 2018 | 20.7% | CN¥2.34 Billion | CN¥2.07 Billion | CN¥268.63 Million | CN¥11.31 Billion | ▲ +1.1 pp |
| 2017 | 19.6% | CN¥1.89 Billion | CN¥1.80 Billion | CN¥94.60 Million | CN¥9.67 Billion | ▲ +4.9 pp |
| 2016 | 14.7% | CN¥1.10 Billion | CN¥1.09 Billion | CN¥9.90 Million | CN¥7.50 Billion | ▼ -8.7 pp |
| 2015 | 23.4% | CN¥796.82 Million | CN¥790.14 Million | CN¥6.68 Million | CN¥3.40 Billion | ▼ -1.3 pp |
| 2014 | 24.7% | CN¥450.66 Million | CN¥450.66 Million | CN¥- | CN¥1.83 Billion | ▲ +2.1 pp |
| 2013 | 22.6% | CN¥372.31 Million | CN¥372.31 Million | CN¥- | CN¥1.65 Billion | ▼ -0.4 pp |
| 2012 | 23.0% | CN¥210.43 Million | CN¥210.43 Million | CN¥- | CN¥916.39 Million | ▲ +8.5 pp |
| 2011 | 14.4% | CN¥118.00 Million | CN¥118.00 Million | CN¥- | CN¥817.11 Million | ▼ -14.0 pp |
| 2010 | 28.4% | CN¥84.12 Million | CN¥84.12 Million | CN¥- | CN¥296.03 Million | ▲ +7.2 pp |
| 2009 | 21.2% | CN¥49.64 Million | CN¥49.64 Million | CN¥- | CN¥234.18 Million | ▼ -15.5 pp |
| 2008 | 36.7% | CN¥41.02 Million | CN¥41.02 Million | CN¥- | CN¥111.89 Million | — |